These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 21227422)

  • 1. The double-faced metabolic and inflammatory effects of standard drug therapy in patients after percutaneous treatment with drug-eluting stent.
    Wu Y; Zhang W; Liu W; Zhuo X; Zhao Z; Yuan Z
    Atherosclerosis; 2011 Mar; 215(1):170-5. PubMed ID: 21227422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-eluting stent, but not bare metal stent, accentuates the systematic inflammatory response in patients.
    Liu J; Zhuo XZ; Liu W; Wan Z; Wang X; Zhang W; Gao S; Yuan Z; Wu Y
    Cardiology; 2014; 128(3):259-65. PubMed ID: 24852180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of inflammatory markers for the prediction of neointimal hyperplasia after drug-eluting stent implantation.
    Kang WC; Il Moon C; Lee K; Han SH; Suh SY; Moon J; Shin MS; Ahn T; Shin EK
    Coron Artery Dis; 2011 Dec; 22(8):526-32. PubMed ID: 21909023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early elevation of interleukin-1beta and interleukin-6 levels after bare or drug-eluting stent implantation in patients with stable angina.
    Sardella G; Mariani P; D'Alessandro M; De Luca L; Pierro M; Mancone M; Porretta A; Accapezzato D; Fedele F; Paroli M
    Thromb Res; 2006; 117(6):659-64. PubMed ID: 16005497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
    Almalla M; Schröder J; Pross V; Marx N; Hoffmann R
    Catheter Cardiovasc Interv; 2014 May; 83(6):881-7. PubMed ID: 23765557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention.
    Meng S; Wang LS; Huang ZQ; Zhou Q; Sun YG; Cao JT; Li YG; Wang CQ
    Clin Exp Pharmacol Physiol; 2012 May; 39(5):406-11. PubMed ID: 22220931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
    Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
    Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.
    Onuma Y; Kukreja N; Daemen J; Garcia-Garcia HM; Gonzalo N; Cheng JM; van Twisk PH; van Domburg R; Serruys PW;
    JACC Cardiovasc Interv; 2009 Jul; 2(7):603-10. PubMed ID: 19628181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percutaneous coronary intervention for acute coronary syndrome due to graft failure: use of bare-metal and drug-eluting stents and subsequent long-term clinical outcome.
    Harskamp RE; Kuijt WJ; Damman P; Beijk MA; Grundeken MJ; Woudstra P; Tijssen JG; de Winter RJ
    Catheter Cardiovasc Interv; 2014 Feb; 83(2):203-9. PubMed ID: 22508617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: results from the first phase of the prospective multicentre German DES.DE registry.
    Abdel-Wahab M; Nienaber CA; Mostafa AE; Sabin G; Tebbe U; Hochadel M; Senges J; Akin I; Kuck KH; Hamm C; Richardt G;
    EuroIntervention; 2011 Jun; 7(2):201-8. PubMed ID: 21646062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute coronary syndrome is an independent risk factor for late incomplete stent apposition after sirolimus-eluting stent implantation.
    Zhang RY; DU R; Zhu ZB; Zhang Q; Hu J; Lü AK; Zhang JS; Shen WF
    Chin Med J (Engl); 2008 Dec; 121(24):2504-8. PubMed ID: 19187586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-eluting stent-supported percutaneous coronary intervention for chronic total coronary occlusion.
    Migliorini A; Moschi G; Vergara R; Parodi G; Carrabba N; Antoniucci D
    Catheter Cardiovasc Interv; 2006 Mar; 67(3):344-8. PubMed ID: 16489559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the first-generation drug-eluting stent implantation on periprocedural myocardial injury in patients with stable angina pectoris.
    Okada T; Yoshikawa D; Ishii H; Matsumoto M; Hayakawa S; Matsudaira K; Tanaka M; Kumagai S; Hayashi M; Ando H; Amano T; Murohara T
    J Cardiol; 2012 Oct; 60(4):264-9. PubMed ID: 22738692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes following coronary drug-eluting- and bare-metal-stent implantation.
    Auer J; Leitner A; Berent R; Lamm G; Lassnig E; Krennmair G
    Atherosclerosis; 2010 Jun; 210(2):503-9. PubMed ID: 20060973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial).
    Valgimigli M; Tricoci P; Huang Z; Aylward PE; Armstrong PW; Van de Werf F; Leonardi S; White HD; Widimsky P; Harrington RA; Cequier A; Chen E; Lokhnygina Y; Wallentin L; Strony J; Mahaffey KW; Moliterno DJ
    Am J Cardiol; 2014 Sep; 114(5):665-73. PubMed ID: 25129064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial assessment of vessel interactions after drug-eluting stent implantation in unprotected distal left main coronary artery disease using frequency-domain optical coherence tomography.
    Fujino Y; Attizzani GF; Bezerra HG; Wang W; Tahara S; Yamamoto H; Chamie D; Kanaya T; Mehanna E; Takagi K; Nakamura S; Costa MA
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1035-45. PubMed ID: 24156964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zotarolimus-eluting vs. sirolimus-eluting coronary stents in patients with and without acute coronary syndromes: a SORT OUT III substudy.
    Thim T; Maeng M; Kaltoft A; Jensen LO; Tilsted HH; Hansen PR; Kelbaek H; Thayssen P; Ravkilde J; Madsen M; Sørensen HT; Thuesen L; Lassen JF
    Eur J Clin Invest; 2012 Oct; 42(10):1047-54. PubMed ID: 22624990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.